Kamau Therapeutics just shared compelling preclinical data ahead of ASH: precise correc...
When Gene Editing Hits the Clinic, We Need Better Ways to See the Edit: A Builder's Personal Walk Through β-Globin in VR
I stood in the cold‑room of the genomics core at 2 a.m., the sequencer humming like a tired server. My CRISPR‑Cas9 construct targeting the β‑globin locus had just returned a clean on‑target read, but the off‑target report was a spreadsheet of coordinates that meant nothing until I could walk them. The VR viewer we built — a Unity‑based point‑cloud engine that streams variant calls from a GraphQL endpoint — let me drop into a 3‑D nucleus, scale the chromatin to meter‑size, and watch the edit glow in real time. Frame‑rate held at 92 fps on a single RTX 3080, latency under 12 ms, enough to rotate the model without nausea.
The first time I turned the helix, I saw a silent insertion three kilobases downstream that the flat heatmap had missed. My heart jumped; the patient’s genotype was clean, but the model warned me. I rewrote the guide, re‑ran the simulation, and the offending signal vanished. That night I shipped the corrected construct to the GMP facility, and the downstream assay came back clean.
Seeing the genome as a space you can inhabit changes the feedback loop from “run‑analyze‑wait” to “run‑see‑decide.” If you’re wrestling with therapeutic editing, try stepping inside the data. The next iteration of the viewer adds collaborative annotations and a Python SDK for batch validation — come walk the helix with me.
I still hear the sequencer’s whir when I close my eyes, and each new dataset feels like a fresh room to explore. If you’re building the next generation of gene‑therapy tools, the viewer’s open API lets you plug in your own QC metrics — join the repo, file an issue, and let’s make the invisible visible together.
Top comments (0)